Merck & Co., Inc. has appealed a decision by the European Patent
Office revoking a new patent that covers the once-weekly
administration of alendronate remains pending.
provides in-depth news coverage of intellectual property lawsuits involving public companies with assets of USD $1 billion or more. Coverage focuses on the infringement of intellectual property rights (including patents, copyrights, trademarks, trade dress, trade secrets, and royalties) and corporate indemnification of intellectual property violations.